Chief Business Officer at evitria
evitria Europe
London, Great Britain
Mail: ds@evitria.com
As Chief Business Officer, Desmond Schofield leads strategic initiatives focused on fostering growth and innovation. His responsibilities include crafting and implementing strategies to enhance customer service and satisfaction within a constantly evolving market.
With a Doctorate in biochemical engineering from the University College London, Desmond Schofield has gained invaluable experience in numerous fields across the biotechnology sector and beyond: he is a professional in business development and new technology ventures; furthermore, Desmond Schofield is experienced in synthetic biology as well as in bioprocessing and immuno-oncology. This and more sums up to a broad portfolio of profound expert knowledge that Desmond Schofield brings to evitria.
LinkedIn profile: Desmond Schofield
Articles
Afucosylated antibodies are either studied or already used in various fields of application. In this article, we will explore some of them.
Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our body and immune system healthy.
Antibody discovery is a key phase in the development of new therapeutic and diagnostic tools. In this article, we will shed light on this process.